secwatch.observer — SEC 8-K summary
======================================

Issuer:     IMMUNIC, INC. (IMUX)
CIK:        0001280776
Form:       8-K
Filed at:   2026-05-27T11:00:48+00:00
Accession:  0001193805-26-000696
Event type: leadership
Sentiment:  positive
Materiality: 0.75
Item codes: 5.02, 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Immunic appoints Erik Lundgren as CEO; Daniel Vitt resigns as CEO but remains on board
--------------------------------------------------------------------------------

- Erik Lundgren appointed CEO effective June 1, 2026; previously SVP at Genentech/Roche, led Ocrevus launch.
- Daniel Vitt resigns as CEO but retains board seat and responsibility for scientific strategy.
- Lundgren receives base salary $685K, target bonus 60%, and initial option for 1M shares under inducement plan.
- Phase 3 ENSURE trial in relapsing MS expected data readout by year-end 2026; Lundgren to lead toward potential NDA and commercialization.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1280776/000119380526000696/0001193805-26-000696-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1280776/000119380526000696/e665513_8k-immunic.htm
  HTML page:      https://secwatch.observer/filing/0001193805-26-000696

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer